Sai Life Sciences Limited has fulfilled its regulatory obligations by submitting the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed this compliance document with both BSE Limited and National Stock Exchange of India Limited on April 8, 2026.

Regulatory Compliance Details

The certificate submission represents a routine quarterly compliance requirement under SEBI regulations. KFin Technologies Limited, serving as the company's Registrar and Share Transfer Agent, issued the certificates dated April 2, 2026. These documents confirm that all necessary details regarding securities transactions have been properly reported to regulatory authorities.

Certificate Scope and Purpose

The certificates address both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) requirements. KFin Technologies Limited, through Deputy Vice President Ganesh Chandra Patro, certified that details of securities dematerialized and rematerialized during the quarter have been furnished to all stock exchanges where Sai Life Sciences shares are listed.

Stock Exchange Filings

Sai Life Sciences maintains listings on major Indian stock exchanges with specific identifiers for trading purposes. The company filed identical certificates with both depositories to ensure comprehensive compliance coverage. Company Secretary and Compliance Officer Runa Karan signed the submission documents, confirming the company's adherence to regulatory timelines.

This quarterly submission demonstrates Sai Life Sciences' commitment to maintaining transparent regulatory compliance and ensuring proper documentation of all securities transactions through authorized depositories.

Sai Life Sciences continues to attract positive attention from leading brokerage firms, with both Jefferies and Morgan Stanley maintaining bullish ratings on the pharmaceutical company. The latest development sees Morgan Stanley upgrading its target price while maintaining an Overweight rating.

Morgan Stanley's Updated Assessment

Morgan Stanley has revised its outlook on Sai Life Sciences, raising the target price to ₹1,160 from the previous ₹1,123 while maintaining its Overweight rating. The upgrade reflects significant earnings revisions and improved growth visibility across key business segments.

Earnings Upgrades and Growth Drivers

The brokerage firm has made substantial upward revisions to its financial estimates, with EBITDA projections increased by 6-8% for the FY26-28 period and EPS estimates upgraded by 9-12%. The strong performance of the discovery segment is driving revenue growth, while robust CDMO demand is enhancing growth visibility.

Jefferies Maintains Positive Stance

Jefferies continues to support Sai Life Sciences with a Buy rating and Rs 1,300 target price. The global brokerage highlighted the company's operational resilience and strong fundamentals:

Market Positioning and Outlook

Both brokerage firms emphasize the company's strong positioning in the pharmaceutical services sector. The combination of robust CDMO demand, effective cost management, and strong pipeline visibility supports the positive investment thesis. The absence of destocking concerns and successful project acquisitions further reinforce the company's competitive advantages in the market.